{"denoms":[{"counts":[{"groupId":"BG000","value":"138"},{"groupId":"BG001","value":"65"},{"groupId":"BG002","value":"234"},{"groupId":"BG003","value":"116"},{"groupId":"BG004","value":"8"},{"groupId":"BG005","value":"9"},{"groupId":"BG006","value":"26"},{"groupId":"BG007","value":"596"}],"units":"Participants"}],"groups":[{"description":"Participants with germline breast cancer gene (gBRCA) mutation received oral dose of niraparib 300 milligrams (mg) once daily in 28-day cycles until disease progression.","id":"BG000","title":"gBRCA Niraparib"},{"description":"Participants with germline BRCA mutation received oral dose of placebo matching niraparib once daily in 28-day cycles until disease progression.","id":"BG001","title":"gBRCA Placebo"},{"description":"Participants without germline BRCA mutation received oral dose of niraparib 300 mg once daily orally in 28-day cycles until disease progression.","id":"BG002","title":"Non-gBRCA Niraparib"},{"description":"Participants without germline BRCA mutation received matching placebo once daily orally in 28-day cycles until disease progression","id":"BG003","title":"Non-gBRCA Placebo"},{"description":"Participants received a single dose of 3x100 mg capsules of niraparib administered orally following a minimum 10-hour overnight fast in Period 1 followed by 300 mg capsules of niraparib administered orally as single dose in fed condition (high-fat meal) in Period 2. There was a washout period of 7 days between treatment periods.","id":"BG004","title":"FE Sub-study: Fasted/Fed"},{"description":"Participants received single dose of 3x100 mg capsules of niraparib administered orally following a high-fat meal in Period 1 followed by 3x100 mg capsules of niraparib administered orally as single dose in fasted condition in Period 2. There was a washout period of 7 days between treatment periods.","id":"BG005","title":"FE Sub-study: Fed/Fasted"},{"description":"Participants received Niraparib 300 mg once daily orally.","id":"BG006","title":"QTc Sub-study: Niraparib"},{"description":"Total of all reporting groups","id":"BG007","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"110"},{"groupId":"BG001","value":"49"},{"groupId":"BG002","value":"130"},{"groupId":"BG003","value":"69"},{"groupId":"BG004","value":"5"},{"groupId":"BG005","value":"5"},{"groupId":"BG006","value":"16"},{"groupId":"BG007","value":"384"}],"title":"Between 18 and 64 years"},{"measurements":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"104"},{"groupId":"BG003","value":"47"},{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"4"},{"groupId":"BG006","value":"10"},{"groupId":"BG007","value":"212"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"138"},{"groupId":"BG001","value":"65"},{"groupId":"BG002","value":"234"},{"groupId":"BG003","value":"116"},{"groupId":"BG004","value":"8"},{"groupId":"BG005","value":"9"},{"groupId":"BG006","value":"26"},{"groupId":"BG007","value":"596"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"2"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"20"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"1"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"3"},{"groupId":"BG007","value":"11"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"123"},{"groupId":"BG001","value":"55"},{"groupId":"BG002","value":"201"},{"groupId":"BG003","value":"101"},{"groupId":"BG004","value":"6"},{"groupId":"BG005","value":"9"},{"groupId":"BG006","value":"21"},{"groupId":"BG007","value":"516"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"19"},{"groupId":"BG003","value":"10"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"46"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"}],"populationDescription":"The baseline analysis population was the intent-to-treat population, defined as all randomized participants with participants analyzed according to the study drug assigned via randomization"}